Science Explorer Back to mapMap
Discussion
Topic · Hematology

Chronic Myeloid Leukemia Treatments

Chronic Myeloid Leukemia Treatments is a research topic within Hematology. Science Explorer counts 31k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.

  • Imatinib
  • BCR-ABL
  • Tyrosine Kinase Inhibitors
  • Resistance
  • Mutation
  • Leukemia Stem Cells
  • Molecular Response
  • Treatment Discontinuation
  • Dasatinib
  • Nilotinib
Research works
31k
fractional, since 1950
In the world top 10%
3.2k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+22%
the tick is no change
Largest producer
United States
39% of the 10 largest, 2022-now
Chronic Myeloid Leukemia Treatments

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Chronic Myeloid Leukemia Treatments research?

By volume, the United States and China publish the most (1.8k and 867 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.8k works
  2. 2 China 867 works
  3. 3 India 329 works
  4. 4 Italy 321 works
  5. 5 Japan 301 works
  6. 6 Germany 252 works
  7. 7 Brazil 218 works
  8. 8 France 203 works
  9. 9 United Kingdom 179 works
  10. 10 Spain 149 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 39.4%China: 18.6%India: 7.1%Italy: 6.9%6 others listed: 28.0%39%largest
United States1,833 · 39.4%China867 · 18.6%India329 · 7.1%Italy321 · 6.9%6 others listed1,301 · 28.0%

Shares of the rows listed above, not of the whole node.

Which institutions lead Chronic Myeloid Leukemia Treatments research?

By volume in 2022-now, The University of Texas MD Anderson Cancer Center publishes the most Chronic Myeloid Leukemia Treatments research, followed by Harvard University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 The University of Texas MD Anderson Cancer CenterUnited States 176 works
  2. 2 Harvard UniversityUnited States 72 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 61 works
  4. 4 Peking UniversityChina 55 works
  5. 5 Mayo ClinicUnited States 48 works
  6. 6 Novartis (Switzerland)Switzerland 35 works
  7. 7 All India Institute of Medical SciencesIndia 35 works
  8. 8 Soochow UniversityChina 32 works
  9. 9 The Ohio State UniversityUnited States 31 works
  10. 10 Zhejiang UniversityChina 30 works

Who are the leading researchers in Chronic Myeloid Leukemia Treatments?

The most-cited researchers publishing on Chronic Myeloid Leukemia Treatments include Robert John Tibshirani, Guido Kroemer and Gad A. Getz.

  1. 1 Robert John Tibshirani United States 396k citations
  2. 2 Guido Kroemer France 386k citations
  3. 3 Gad A. Getz United States 364k citations
  4. 4 Elaine R. Mardis United States 346k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Shizuo Akira Japan 342k citations
  7. 7 Jun Wang China 340k citations
  8. 8 Gregory Y.H. Lip United Kingdom 311k citations
  9. 9 Richard A. Gibbs United States 292k citations
  10. 10 Todd R. Golub United States 283k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Chronic Myeloid Leukemia Treatments?

The most cited paper in Chronic Myeloid Leukemia Treatments is "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel" (Hartmut Döhner et al., 2016), with 5,972 citations. Next come "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" (5,296) and "The resurgence of platinum-based cancer chemotherapy" (4,748).

Most cited papers
#PaperReleasedCitations
1 Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Hartmut Döhner et al. · Blood Open access 28 Nov 2016 5,972
2 Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Brian J. Druker, Moshe Talpaz, Debra J. Resta et al. · New England Journal of Medicine Open access 5 Apr 2001 5,296
3 The resurgence of platinum-based cancer chemotherapy Lloyd R. Kèlland · Nature reviews. Cancer Review 12 Jul 2007 4,748
4 Genomic Classification and Prognosis in Acute Myeloid Leukemia Elli Papaemmanuil et al. · New England Journal of Medicine Open access 8 Jun 2016 4,520
5 Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri et al. · New England Journal of Medicine Open access 15 Aug 2002 4,425
All 100 most cited papers, with filters and sorting

Where is Chronic Myeloid Leukemia Treatments research done?

The largest centres of Chronic Myeloid Leukemia Treatments research in 2022-now are Houston (United States), Beijing (China), New York (United States) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Houston and Augusta.

Largest cities, 2022-now

  1. 1 HoustonUnited States 201 works
  2. 2 BeijingChina 148 works
  3. 3 New YorkUnited States 115 works
  4. 4 TokyoJapan 77 works
  5. 5 BostonUnited States 75 works
  6. 6 ParisFrance 72 works
  7. 7 RomeItaly 69 works
  8. 8 São PauloBrazil 68 works
  9. 9 LondonUnited Kingdom 66 works
  10. 10 GuangzhouChina 65 works

Where it is the local speciality

  1. HoustonUS · 201.2 works13×
  2. AugustaUS · 20.8 works13×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Chronic Myeloid Leukemia Treatments than the world average.

See Chronic Myeloid Leukemia Treatments on the map

Where is the best place to study Chronic Myeloid Leukemia Treatments?

Among universities, judged by research, Harvard University, Augusta University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 16.25%fractional works in this field (log) →share of work in the world top 10% →Université Paris CitéHarvard UniversityAugusta UniversityChinese Academy of M…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 90.619.1%4.2×72 +23.9%
2Augusta UniversityUnited States 67.016.8%21.0×21 +92.0%
3Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 65.810.8%10.7×61 +80.9%
4Université Paris CitéFrance 63.820.6%5.6×23 -3.2%
5Oregon Health & Science UniversityUnited States 63.815.5%10.9×20 +29.0%
6Peking UniversityChina 63.411.2%4.9×54 +50.2%
7Stanford UniversityUnited States 62.516.6%2.1×17 +43.6%
8Yale UniversityUnited States 62.412.4%4.5×26 +53.1%
9University of MiamiUnited States 60.920.2%5.1×17 +98.8%
10Washington University in St. LouisUnited States 59.919.3%4.6×18 +33.3%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Chronic Myeloid Leukemia Treatments, country by country

Is Chronic Myeloid Leukemia Treatments research growing?

Output in 2022-2025 was 22% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Chronic Myeloid Leukemia Treatments.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Chronic Myeloid Leukemia Treatments as a percentage of every work published that year, 0.027% in 2024.

still counting0.020%0.040%Chronic Myeloid Leukemia Treatments0.027% in 202519801990200020102020

Fractional works of Chronic Myeloid Leukemia Treatments over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Chronic Myeloid Leukemia Treatments10.5% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Chronic Myeloid Leukemia Treatments. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.